Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

Frontiers in Immunology

Brian C. Healey¹  Rafael M. Rezende¹  Thais G. Moreira¹  Saef Izzy¹  Howard L. Weiner¹  Clare M. Baecher-Allan¹  Karen Chen²  Kimble T. F. Matos³  Gerson D. Keppeke³  Marcelle G. Spinola³  Giovana S. De Paula⁴  Rogerio A. Dedivitis⁴  Fernando C. Pansera⁴  Raquel G. Da Mata⁴  Thais M. M. Santana⁴  Andre S. Cortina⁴  Kunwar Shailubhai⁵  Jules Jacob⁵  Vaseem Palejwala⁵ 

[1] Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States;Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States;Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil;Santa Casa de Misericordia de Santos, Santos, Brazil;Tiziana LifeScience, Doylestown, PA, United States;

关键词: foralumab;    anti-CD3;    COVID-19;    SARS-CoV-2;    immune responses;   

DOI  :  10.3389/fimmu.2021.815812

来源: DOAJ

【 授权许可】

Unknown